In a statement, Gilead Sciences (GILD -0.2%) reports that its manufacturing network for COVID-19 med Veklury (remdesivir) has surpassed 40 countries in North America, Europe and Asia. Supply is up 50-fold since January. More than 2M courses of treatment will be produced by year-end with “several million more” potentially available in 2021 if needed.
The company has inked non-exclusive licensing agreements with nine generic drug makers expanding supply to 127 low-income and lower-middle-income countries. Technology transfers have been completed and manufacturing has begun.
Veklury remains the only drug approved in major markets for the treatment of severe cases of the respiratory infection.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.